Publikovat

Mercury77
Mercury77
#ModernaQ3VaccineSales My take on Moderna (MRNA) Q3: I am leaning YES on beating earnings. The bar is very low — consensus is -$1.10 EPS on ~$890M revenue, vs -$0.51 on $1.02B last year. In Q2 they already beat with -$1.97 on $145M revenue vs $103M expected. The real story is not COVID anymore, it's the cancer vaccine data. That is why the stock is up almost 8x from its low this year.

Zřeknutí se odpovědnosti: Obsah v síti OKX Orbit je poskytován pouze pro informační účely. Další informace

Odpovědi

Zatím žádné komentáře. Odpovězte jako první!